



# BIOMEDICAL ENTERPRISE PROGRAM (BEP) Integrative Stream Subjects

Open to MIT and Harvard students, Integrative Stream subjects are only one component of BEP's intensive curriculum designed to train the next generation of leaders for biomedical enterprises. Graduates exit BEP with a deep understanding of the language and process of biomedical science, technology and patient care. This in combination with world-class management training at Sloan means that graduates enter the business world in command of the skills needed to develop and commercialize products for the healthcare industry.

# 15.363J/HST.971J Building a Biomedical Business

The class focuses on the strategic and organizational challenges of creating and building an entrepreneurial biomedical business, examining strategies and organizational choices for taking an idea and transforming it into a sustainable business.

Course director: F. Murray. Fall, W 5:30-8:30 p.m.

# HST.975J/15.121J

# **Clinical Trials and Biomedical Enterprise**

What are the ramifications of doing a clinical trial? This course critically examines the regulations pertaining to clinical trials, the role of trials in FDA approvals, and the expense of clinical trials.

Course directors: H. Golub

Spring, T 6-8:00 p.m.

# HST.977J/15.122J

# Critical Reading & Technology Assessment of Biomedical Info.

Where is the reality within any scientific controversy? Does that reality provide a commercial opportunity? The course will explore these questions in the context of real scientific debate. Course directors: S. Lapidus, B. Seed. Next offering Fall 2005

## 15.141J/HST.918J

# **Economics of Health Care Industries**

Topics to be considered include the economic rationale for biomedical product innovation, the economics of reimbursement, and cost-benefit analysis.

Course directors: E. Berndt, S. Finkelstein.

Spring, R 4-7:00 p.m.

# HST.979J/15.123J

# **Dynamics of Biomedical Technologies**

This seminar examines the interrelationships between life science and technology developments in the context of six dynamic forces affecting the biomedical industrial sector. In general, these interrelationships will be considered by closely investigating one science or technology platform during each semester. Specific case studies and company presentations will be used to foster discussion and in-depth analysis. Course directors: A. Sinskey, Fall; R. Cohen, Spring Fall, M 3-5:00 p.m. & Spring 2005, W 3-5:00 p.m. (H1)

# 15.136J/HST.920J Principles and Practice of Drug Development

The course describes and critically assesses the major issues and stages of developing a pharmaceutical or biopharmaceutical, including drug discovery, preclinical development, clinical investigation, manufacturing and regulatory issues for small and large molecules, and the economic and financial considerations of the drug development process. Instruction offers a multi-disciplinary perspective from faculty in the clinical, life, and management sciences, as well as from industry guests.

Course directors: T. Allen, C. Cooney, S. Finkelstein, R. Rubin, A. Sinskey. Fall, R 3-6:00 p.m.

#### 15.963

### **Medical Innovations**

This subject will explore the application of technology to medicine. Physicians from various specialties will describe their work, with emphasis on the hurdles that limit optimal patient care.

Course director: G. Bitran, M. Gray et al. Spring, MW 4:30-6:00 p.m.

### **HST.572**

## **Future Medical Technologies**

In a seminar setting, students interact with biomedical scientists, engineers, and entrepreneurs directly involved in creating new companies based on future technologies. Topics include pharmaceuticals, drug delivery and medical devices.

Course Director: J. Weaver. Spring, W 6-7:30 p.m.

